A recent primary neuronal culture study of DIV8 revealed that EGCG was able to enhance the clearance of AD-related phosphorylated tau species, indicating that EGCG could be used as an adjuvant agent for AD treatment [38]. This evidence concerns the gene MAPT and Alzheimer disease.